PROGNOSTIC AND THERAPEUTIC ROLE OF NUCLEAR FACTORkappa B (NF-κB) IN BREAST CANCER

Authors

  • Ayesha Ahmed

Abstract

Nuclear Factor- kappa B (NF-κB) is an essential transcription factor that not only modulates cellularresponses to stress but also plays a pivotal role in inflammation, immunity, cell cycle growth andsurvival. NF-κB-regulated genes have been documented to be involved in cellular proliferation andinvasion along with tumour related angiogenesis and lymphangiogenesis. Dysregulation of NF-κBassociated pathways are seen in multiple malignancies. Its constitutive activation in the clinicallyaggressive and prognostically poor ER-negative, Her2-neu positive and inflammatory breast cancercould formulate the basis for its evolution as a potential prognostic and therapeutic target.Keywords: Nuclear Factor kappa B, NF-κB, Breast Cancer, ER-negative

References

Baldwin AS Jr. The NF-κB, IkB proteins: new discoveries and

insights. Annu Rev Immunol 1996;14:649–83.

Finco TS, Baldwin AS. Mechanistic aspects of NF-κB regulation:

the emerging role of phosphorylation and proteolysis. Immunity

;3:263–72.

Barnes PJ, Karin M. Nuclear factor-kB—A pivotal transcription

factor in chronic inflammatory diseases. New Engl J Med

;366:1066–71.

Hayden M, Ghosh S: Signaling to NF-κB. Genes & Development

;18:2195–224.

Bonizzi G, Karin M. The two NF-κB activation pathways and

their role in innate and adaptive immunity. Trends in Immunology

;25(6):280–8.

Pasparakis M, Luedde T, Schmidt-Supprian M: Dissection of the

NF-κB signalling cascade in transgenic and knockout mice. Cell

Death & Differentiation 2006;13:861–72.

Pahl HL. Activators and target genes of Rel/NF-κB transcription

factors. Oncogene 1999;18(49):6853–66.

Ghosh S, May M, Kopp E. NF-κB and rel proteins:

Evolutionarily conserved mediators of immune responses. Ann

Rev Immunol 1998;16:225–60.

Miron PL. Mutational Analysis of NF-κB in Breast Cancer.

(Developmental Pilot Project) available at

http://www.dfhcc.harvard.edu/fileadmin/DFHCC_Admin/SPOR

Es/Breast/Penelope_Miron_Dev_Project.pdf

Sen R, Baltimore D. Multiple nuclear factors interact with the

immunoglobulin enhancer sequences. Cell 1986;46:705–16.

Ghosh S, Karin M. Missingpieces in the NF-nB puzzle. Cell

;109:S81–96.

Li Q, Verma IM. NF-κB regulation in the immune system. Nat

Rev Immunol 2002;2:725–34.

Tergaonkar V, Pando M, Vafa O, Wahl G, Verma I.p53

stabilization is decreased upon NFkappaB activation: a role for

NFkappaB in acquisition of resistance to chemotherapy. Cancer

Cell 2002;1(5):493–503.

Biswas DK, Martin KJ, McAlister C. Apoptosis caused by

chemotherapeutic inhibition of nuclear factor-nB activation.

Cancer Res 2003;63:290–5.

Wang Y, Paszek P , Horton CA, Kell DB, White MRH,

Broomhead DS, et al. Interactions among oscillatory pathways in

NF-kappa B signaling: BMC Systems Biology 2011;5:23–8.

Burkett M, Gilmore TD. Control of apoptosis by Rel/NF-nB

transcription factors. Oncogene 1991;8:6910–24.

Scott ML, Fujita T, Liou HC, Nolan GP, Baltimore D: The p65

subunit of NF-kappa B regulates I kappa B by two distinct

mechanisms. Genes & Development 1993;7(7a):1266–76.

Song HY, Rothe M, Goeddel DV. The tumor necrosis factorinducible zinc finger protein A20 interacts with TRAF1/TRAF2

and inhibits NF-kappaB activation. Proc Natl Acad Sci USA

;93(13):6721–5.

Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri

S, et al. De-ubiquitination and ubiquitin ligase domains of A20

downregulate NF-κB signalling. Nature 2004;430:694–9.

Ahmad M, Marui N, Alexander RW, Medford RM. Cell typespecific transactivation of the VCAM-1 promoter through an NF-

κB enhancer motif. J Biol Chem 1995;270:8976–83.

Paxton LL, Li LJ, Secor V, Duff JL, Naik SM, Shibagaki N.

Flanking sequences for the human intercellular adhesion

molecule-1 NF-κB response element are necessary for tumor

necrosis factor a-induced gene expression. J Biol Chem

;272:15928–35.

Aoudjit F, Brochu N, Belanger B, Stratowa C, Hiscott J, Audette

M. Regulation of intercellular adhesion molecule-1 gene by tumor

necrosis factor-a is mediated by the nuclear factor-kB

heterodimers p65/p65 and p65/c-Rel in the absence of p50. Cell

Growth Differ 1997;8:335–42.

Vandermeeren M, Janssens S, Borgers M, Geysen J.

Dimethylfumarate is an inhibitor of cytokine-induced E-selectin,

VCAM-1, and ICAM-1 expression in human endothelial cells.

Biochem Biophys Res Commun 1997;234:19–23.

Lee DH, Tam SS, Wang E, Taylor GR, Plante RK, Lau CY. The

NF-κB inhibitor, tepoxalin, suppresses surface expression of the

cell adhesion molecules CD62E, CD11b/CD18 and CD106.

Immunol Lett 1996;53:109–13.

Ray P, Yang L, Zhang DH, Ghosh SK, Ray A. Selective

upregulation of cytokine-induced RANTES gene expression in

lung epithelial cells by overexpression of IkBR. J Biol Chem

;272:20191–7.

Widmer U, Manogue KR, Cerami A, Sherry B. Genomic cloning

and promoter analysis of macrophage inflammatory protein

(MIP)-2, MIP-1 alpha, and MIP-1 beta, members of the

chemokine superfamily of proinflammatory cytokines. J Immunol

;150:4996–5012.

Blackwell TS, Christman JW. The role of nuclear factor-kappa B

in cytokine gene regulation. Am J Respir Cell Mol Biol

;17:3–9.

Gilmore TD. Clinically relevant finding. J Clin Investig

;100:2935–6.

Garside H, Stevens A, Farrow S, Normand C, Houle B, Berry A,

et al. Glucocorticoid ligands specify different interactions with

NF-kappa B by allosteric effects on the glucocorticoid receptor

DNA binding domain. J Biol Chem 2004;279(48):50050–9.

Ikeda A, Sun X, Li Y, Zhang Y, Eckner R, Doi T, et al.

p300/CBP-dependent and -independent transcriptional

interference between NF-kappa B RelA and p53. Biochem

Biophys Res Comm 2000;272(2):375–9.

Perkins ND. Integrating cell-signalling pathways with NF-κkB

and IKK function. Nat Rev Mol Cell Biol 2007;8:49–62.

Salminen A, Ojala J, Huuskonen J, Kauppinen A, Suuronen T,

Kaarniranta K. Interaction of aging-associated signaling cascades:

Inhibition of NF-kappa B signaling by longevity factors FoxOs

and SIRT1. Cell Mol Life Sci 2008;65(7-8):1049–58.

Wadgaonkar R, Phelps K, Haque Z, Williams A, Silverman E,

Collins T. CREB-binding protein is a nuclear integrator of nuclear

factor-kappa B and p53 signaling. J Biol Chem

;274(4):1879–82.

Culmsee C, Siewe J, Junker V, Retiounskaia M, Schwarz S,

Camandola S. Reciprocal inhibition of p53 and nuclear factor-κB

transcriptional activities determines cell survival or death in

neurons. J Neurosci 2003;23(24):8586–95.

Nakshatri H, Goulet RJ, Jr. NF-kB and breast cancer. Curr Probl

Cancer 2002;26:282–309.

Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ, Jr., Sledge

GW, Jr. Constitutive activation of NF-nB duringprog ression of

breast cancer to hormone-independent growth. Mol Cell Biol

;17:3629–39.

Cao Y, Karin M: NF-kappaB in mammary gland development and

breast cancer. J Mammary Gland Biol Neoplasia 2003;8:215–23.

Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin AS Jr.

Selective activation of NF-kappa B subunits in human breast

cancer: potential roles for NF-kappa B2/p52 and for Bcl-3.

Oncogene 2000;19:1123–31.

Huber MA, Azoitei N, Baumann B, Grunert S, Sommer A,

Pehamberger H, et al. NF-kappaB is essential for epithelialmesenchymal transition and metastasis in a model of breast

cancer progression. J Clin Invest 2004;114:569–81.

Edwards J, Tannahill C, Obondo C, Elsberger B, Mallon E,

Wilson C et al. Expression and activation of Akt and NFkB in

breast cancer patients. Euro J Cancer Suppl 2010;8(6):5–6.

J Ayub Med Coll Abbottabad 2010;22(3)

http://www.ayubmed.edu.pk/JAMC/PAST/22-3/Ayesha.pdf 221

Aggarwal BB. Nuclear factor-kappaB the enemy within. Cancer

Cell 2004;6:203–8.

Karin M, Cao Y, Greten FR, Li ZW: NF-kappaB in cancer:

from innocent bystander to major culprit. Nat Rev Cancer

;2:301–10.

Biswas DK, Shi Q, Bailey S. NF-kB activation in human breast

cancer specimens and its role in cell proliferation and apoptosis.

Proc Natl Acad Sci USA 2004;101:10137–42.

Biswas DK, Iglehart JD. Linkage between EGFR family receptors

and nuclear factor kappaB(NF-kappaB) signalling in breast

cancer. J Cell Physiol 2006;209(3):645‒52.

Singh S, Shi Q, Bailey ST, Palczewski MJ, Pardee AB, Iglehart

JD, Biswas DK. Nuclear factor-kappaB activation: a molecular

therapeutic target for estrogen receptor-negative and epidermal

growth factor receptor family receptor-positive human breast

cancer. Mol Cancer Ther 2007;6(7):1973–82.

Cristofanilli M, Buzdar AU, Hortobagyi GN. Update on the

management of inflammatory breast cancer. Oncologist

;8:141–8.

Smith I. Goals of treatment for patients with metastatic breast

cancer. Semin Oncol 2006;33:2S–5S.

Van Laere SJ, Van der Auwera I, Van den Eynden GG, Elst HJ,

Weyler J, Harris AL, van Dam P, et al. Nuclear factor-kappaB

signature of inflammatory breast cancer by cDNA microarray

validated by quantitative real-time reverse transcription-PCR,

immunohistochemistry, and nuclear factor-kappaB DNA-binding.

Clin Cancer Res 2006;12(11 Pt 1):3249–56.

Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Nasser V,

Loriod B, et al. Gene Expression Profilingfor Molecular

Characterization of Inflammatory Breast Cancer and Prediction of

Response to Chemotherapy. Cancer Res 2004;64:8558–65.

Van Laere S, Van der Auwera I, Van den Eynden GG, Fox SB,

Bianchi F, Harris AL, et al. Distinct molecular signature of

inflammatory breast cancer by cDNA microarray analysis. Breast

Cancer Res Treat 2005;93:237–46.

Lerebours F, Vacher S, Andrieu C, Espie M, Marty M, Lidereau

R. NF-kappa B genes have a major role in Inflammatory Breast

Cancer: BMC Cancer 2008;8:41.

Helbig G, Christopherson KW 2nd, Bhat-Nakshatri P, Kumar S,

Kishimoto H, Miller KD et al. NF-kappaB promotes breast cancer

cell migration and metastasis by inducing the expression of the

chemokine receptor CXCR4. J Biol Chem 2003;278(24):21631–8.

Downloads

Published

2010-09-01

Most read articles by the same author(s)